Synergy of retinoic acid and BH3 mimetics in MYC(N)-driven embryonal nervous system tumours
Open Access
- 28 June 2024
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 131 (4) , 763-777
Abstract
Background: Certain paediatric nervous system malignancies have dismal prognoses. Retinoic acid (RA) is used in neuroblastoma treatment, and preclinical data indicate potential benefit in selected paediatric brain tumour entities. However, limited single-agent efficacy necessitates combination treatment approaches. Methods: We performed drug sensitivity profiling of 76 clinically relevant drugs in combination with RA in 16 models (including patient-derived tumouroids) of the most common paediatric nervous system tumours. Drug responses were assessed by viability assays, high-content imaging, and apoptosis assays and RA relevant pathways by RNAseq from treated models and patient samples obtained through the precision oncology programme INFORM (n = 2288). Immunoprecipitation detected BCL-2 family interactions, and zebrafish embryo xenografts were used for in vivo efficacy testing. Results: Group 3 medulloblastoma (MBG3) and neuroblastoma models were highly sensitive to RA treatment. RA induced differentiation and regulated apoptotic genes. RNAseq analysis revealed high expression of BCL2L1 in MBG3 and BCL2 in neuroblastomas. Co-treatments with RA and BCL-2/XL inhibitor navitoclax synergistically decreased viability at clinically achievable concentrations. The combination of RA with navitoclax disrupted the binding of BIM to BCL-XL in MBG3 and to BCL-2 in neuroblastoma, inducing apoptosis in vitro and in vivo. Conclusions: RA treatment primes MBG3 and NB cells for apoptosis, triggered by navitoclax cotreatment.Keywords
This publication has 72 references indexed in Scilit:
- ERBB and P‐glycoprotein inhibitors break resistance in relapsed neuroblastoma models through P‐glycoproteinMolecular Oncology, 2022
- Efficacy of Carboplatin and Isotretinoin in Children With High-risk MedulloblastomaJAMA Oncology, 2021
- Mechanistic insights into p53‐regulated cytotoxicity of combined entinostat and irinotecan against colorectal cancer cellsMolecular Oncology, 2021
- The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variantsActa Neuropathologica, 2016
- Analysis of the interplay between all-trans retinoic acid and histone deacetylase inhibitors in leukemic cellsArchives of Toxicology, 2016
- Risk stratification of childhood medulloblastoma in the molecular era: the current consensusActa Neuropathologica, 2016
- Molecular subgroups of medulloblastoma: the current consensusActa Neuropathologica, 2011
- Combination of all-trans retinoic acid and taxol regressed glioblastoma T98G xenografts in nude miceApoptosis, 2007
- Clinical trial of valproic acid and all‐trans retinoic acid in patients with poor‐risk acute myeloid leukemiaCancer, 2005
- Pharmacokinetic studies of 13- cis -retinoic acid in pediatric patients with neuroblastoma following bone marrow transplantationCancer Chemotherapy and Pharmacology, 1996